Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 2/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | CFD | P00746 | 1/20 | 0.42 |
| ▸ | TPSB2 | P20231 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 5/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.34 |
| ▸ | GCK | P35557 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14658530 | 0.87 | FFAR1 (0.50) | PTGESFFAR1MEN1KMT2AL3MBTL1 | |
| SCHEMBL3867999 | 0.82 | CFD (0.44) | PTGESFFAR1CFDTPSB2 | |
| SCHEMBL233639 | 0.80 | PTGES (0.44) | PTGESFFAR1MEN1KMT2AL3MBTL1 | |
| SCHEMBL3863909 | 0.78 | CFD (0.37) | FFAR1CFDTPSB2 | |
| SCHEMBL3859065 | 0.78 | CFD (0.48) | PTGESCFDTPSB2GRM5 | |
| SCHEMBL3864997 | 0.74 | CHRNB4 (0.38) | CFDTPSB2 | |
| SCHEMBL3870082 | 0.74 | HTR2A (0.46) | CFDTPSB2KMT2A | |
| SCHEMBL3860077 | 0.74 | CFD (0.35) | CFDTPSB2PTGDR2 | |
| SCHEMBL3865711 | 0.74 | CFD (0.45) | FFAR1CFDTPSB2KMT2A | |
| SCHEMBL29997548 | 0.73 | GRM5 (0.49) | PTGESFFAR1MEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895782-B2 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20140213617-A1 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2014-07-31 | — | — | US | disclosed |
| EP-2076122-A2 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | Acucela, Inc. (US) | 2009-07-08 | — | — | EP | disclosed |
| WO-2009005794-A2 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213617-A1 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, STARD3, PDE6C | PTGES 198/4885FFAR1 1035/4885CFD 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.